Skip to content
Research Article Open access CC BY 4.0

Prevalence and Risk Factors of Potential Drug Interactions in Hospitalized Cardiovascular Patients Using Three Knowledge Bases

Heba Y. Raslan, Ayman K. M. Hassan, Mona M. M. El-Mahdy, Tahani H. Elfaham

Journal of Advances in Medical and Pharmaceutical Sciences · pp. 1–18 · Published 12 Oct 2018

10.9734/JAMPS/2018/44526

Abstract

Background: Drug interactions continue to be an important cause of adverse effects, especially with cardiovascular drugs. Objective: This cross-sectional observational study aimed to recognize the frequency of potential drug-drug interactions (pDDIs) using three electronic knowledge bases (KBs); Lexicomp®, Micromedex®, and the free Drugs.com®, compare the inclusion and gradings of pDDIs in these three KBs and to identify associated risk factors. Methods: Medication orders of 125 patients in the cardiovascular department and its intensive care unit (ICU) of Assiut University Hospitals, Egypt were screened for pDDIs. Results: About 88.8% of the patients were prescribed five or more drugs. A sum of 1206 pDDIs was found which comprised of 245 different interacting pairs. Overall, 96.8% of the patients had at least one pDDI. Moderate risk pDDIs represented the most frequent risk level at 72.24%. Statistical analysis of data by multivariate regression has shown that the number of drugs prescribed could significantly predict the number of pDDIs (p<0.001). This was confirmed by bootstrapped Spearman's correlation (rs(123)=0.808; bias-corrected and accelerated [BCa] 95% confidence interval, 0.719–0.873; p<0.001). Drugs.com® alerted the largest number of pDDIs. Both Drugs.com® and Lexicomp® have shown that most prevalent pDDIs were moderate and that contraindicated were the least, while the major grading was the largest in Micromedex®. Conclusion: A high prevalence of pDDIs was detected, and polypharmacy was a major risk factor. Physicians need to determine the most relevant approach to check for pDDIs while balancing between excessive alerting and overriding of interacting drug pairs. the Integration of medication review guidelines and computerized alert systems should be considered.

Drug interactions cardiovascular medication safety prevalence risk factors hospitalized patients

References (27)

  1. 1 The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
  2. 2 Drug-Drug Interactions Among Elderly Patients Hospitalized for Drug Toxicity [DOI]
  3. 3 Pharmacokinetic drug-drug interaction and their implication in clinical management.
  4. 4 Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association [DOI]
  5. 5 Drug-induced impairment of renal function [DOI]
  6. 6 Hyperkalemia Associated with Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers [DOI]
  7. 7 Amiodarone: guidelines for use and monitoring.
  8. 8 Comparative assessment of four drug interaction compendia [DOI]
  9. 9 High-priority drug–drug interactions for use in electronic health records [DOI]
  10. 10 Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil [DOI]
  11. 11 Assessment of potential drug–drug interactions and its associated factors in the hospitalized cardiac patients [DOI]
  12. 12 Drug Interaction and Pharmacist [DOI]
  13. 13 The cardiotoxicity of macrolides: a systematic review [DOI]
  14. 14 Comparison of three commercial knowledge bases for detection of drug-drug interactions in clinical decision support [DOI]
  15. 15 Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease [DOI]
  16. 16 The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study [DOI]
  17. 17 Clinical relevance of clopidogrel-proton pump inhibitors interaction [DOI]
  18. 18 Potential drug-drug interactions in pediatric patients admitted to intensive care unit of Khyber Teaching Hospital, Peshawar, Pakistan: A cross-sectional study [DOI]
  19. 19 Iatrogenic Diseases as a Reason for Admission to the Intensive Care Unit [DOI]
  20. 20 Risk of digoxin intoxication in heart failure patients exposed to digoxin–diuretic interactions: a population‐based study [DOI]
  21. 21 Comparative analysis of three drug–drug interaction screening systems against probable clinically relevant drug–drug interactions: a prospective cohort study [DOI]
  22. 22 Warfarin-drug interactions: An emphasis on influence of polypharmacy and high doses of amoxicillin/clavulanate [DOI]
  23. 23 When Nutraceuticals Reinforce Drugs Side Effects: A Case Report [DOI]
  24. 24 A Practical Approach to Avoiding Cardiovascular Adverse Effects of Psychoactive Medications [DOI]
  25. 25 Alerts in Clinical Information Systems: Building Frameworks and Prototypes [DOI]
  26. 26 Incidence of Potential Drug-Drug Interaction and Related Factors in Hospitalized Neurological Patients in two Iranian Teaching Hospitals.
  27. 27 Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. [DOI]

Cited by 6

Potentially Harmful Drug–Drug Interactions and Their Associated Factors Among Hospitalized Cardiac Patients: A Cross-Sectional Study

Abdulrahman Kalash, Aly Abdelrahman, Ibrahim Al-Zakwani · Drugs - Real World Outcomes · 2023

Showing 1 of 6 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

67

Page views

0

PDF downloads

55

Outbound clicks

6

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.